|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
The price of shares in AIM-listed immunotherapy specialist Scancell Holdings (LON:SCLP) has dropped by 5.31% to 6.87p (as of 13:15 BST) after it provided an update on a set of stage 2 trials. The company said that it has chosen to withdraw its US trial application for the time after the FDA requested additional information about the third party delivery device. The testing at UK sites should now be able to proceed as planned.
CEO Cliff Holloway commented: “We are pleased to be able to advance our SCIB1 Phase 2 trial in the UK as we believe that SCIB1 administration with an immune checkpoint inhibitor such as pembrolizumab has the potential to offer greater efficacy than when either agent is used alone. Whilst it is disappointing that discussions in the US have taken longer than anticipated, we will continue our dialogue with both Ichor and the Agency, and plan to resubmit the IND as soon as possible“.